Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-31

Howdy.

Sorry for the confusion.

I was referring to the last two CR's, I also do not expect a local component on this US IPO.
I expect these 2 raises included close associates & friends as they needed working capital to cover 6 month delay in Pulse FDA clearance and decision to move from OTC to a NASDAQ listing, pushing out the large capital injection by 12 months.

Feb 2023 CR

Placement led with strong demand from domestic institutions, family offices, and sophisticated investors with Director support to secure firm commitments to raise $4.50 million at $0.30 per share;

August 2002 Cr

Placement led by Directors with strong demand from domestic institutions, family offices, and sophisticated investors securing firm commitments to raise $4.33m million at $0.30 per share;